Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Inclusion Criteria: * Pathologically confirmed diagnosis of non-small cell lung cancer with EGFR mutation * Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by AJCC 7th Edition staging criteria * Surgical resection with curative intent was at least 6 months prior to enrollment * At least 3 weeks have passed since completion of adjuvant chemotherapy or radiotherapy Exclusion Criteria: * Pregnant or breastfeeding * History of allergic reactions attributed to compounds of similar chemical composition to afatinib * Prior exposure to EGFR tyrosine kinase inhibitor * Evidence of clinically active interstitial lung disease * Radiographic evidence of recurrent NSCLC prior to afatinib treatment * Receipt of any experimental treatment within 30 days of start of treatment with afatinib until the end of treatment visit * Use of potent P-gp inhibitors and potent P-gp inducers must be avoided during treatment with afatinib * Individuals with a history of a different malignancy (except: synchronous or metachronous primary non-small cell lung cancers of lower stage than the cancer for which adjuvant treatment is currently being prescribed; disease free for at least 3 years; cervical cancer in situ; basal or squamous cell carcinoma of the skin) * HIV positive on combination antiretroviral therapy * Uncontrolled intercurrent illness